Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.

Yi, Yong Weon

Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. [electronic resource] - Oncotarget Jul 2013 - 984-94 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1949-2553

10.18632/oncotarget.1070 doi


Acetylation--drug effects
Apoptosis--physiology
Boronic Acids--pharmacology
Cell Line, Tumor
Cell Proliferation--drug effects
Chalcones--pharmacology
Female
Gene Expression--drug effects
Humans
Molecular Targeted Therapy
RNA, Small Interfering--genetics
Sirtuin 1--genetics
Transfection
Triple Negative Breast Neoplasms--drug therapy
Tumor Suppressor Protein p53--genetics